Epidiolex (Cannabidiol) Market Report 2026

The epidiolex (cannabidiol) market size has grown strongly in recent years. It will grow from $3.85 billion in 2025 to $4.2 billion in 2026 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to unmet epilepsy treatment needs, regulatory approvals for CBD drugs, pediatric seizure prevalence, neurologist adoption, clinical trial evidence.

The epidiolex (cannabidiol) market size is expected to see strong growth in the next few years. It will grow to $5.9 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to expanded epilepsy indications, cannabinoid research growth, improved reimbursement access, global regulatory acceptance, patient awareness. Major trends in the forecast period include growing adoption of cannabidiol-based therapies, increased focus on rare pediatric epilepsy, expansion of oral solution formulations, rising physician acceptance of CBD drugs, emphasis on long-term seizure control.

The increasing prevalence of epilepsy is expected to drive the growth of the epidiolex (cannabidiol) market in the coming years. Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. The rise in epilepsy cases is linked to factors such as improved diagnosis, greater awareness, and the increasing prevalence of conditions like brain injuries, stroke, and genetic predispositions. Epidiolex is a prescription medication derived from cannabidiol (CBD) that helps treat specific types of epilepsy by reducing the frequency and severity of seizures through modulation of brain signaling pathways. For example, in March 2023, Epilepsy Action, a UK-based non-profit organization, reported that in Northern Ireland, one in 83 people has epilepsy, the highest prevalence among UK nations, compared to one in 107 across the UK. Therefore, the growing incidence of epilepsy is driving the epidiolex (cannabidiol) market.

The increasing healthcare insurance coverage is expected to support the growth of the epidiolex (cannabidiol) market going forward. Healthcare insurance coverage refers to the proportion of the population that has access to medical care through private or government-sponsored insurance plans. Coverage is expanding as more individuals and families recognize the benefits of health protection and prioritize obtaining insurance to access timely medical care. Epidiolex (cannabidiol) plays a key role by providing an effective treatment for rare seizure disorders, with insurance coverage facilitating patient access. For instance, in September 2024, the US Census Bureau reported that in 2023, 92% of the population, or 305.2 million people, had health insurance for some or all of the year. Medicare coverage increased slightly by 0.2 percentage points, covering 18.9% of the population. Therefore, the growth in healthcare insurance coverage is driving the epidiolex (cannabidiol) market.

Key companies in the epidiolex (cannabidiol) market are developing innovative products, such as synthetic cannabidiol (CBD) formulations, to gain a competitive advantage. Synthetic cannabidiol (CBD) is a laboratory-produced version of CBD designed to replicate the therapeutic effects of natural CBD without containing tetrahydrocannabinol (THC). For instance, in January 2024, Akumentis Healthcare Ltd., an India-based pharmaceutical company, launched Clasepi, a DCGI-approved synthetic CBD product for treating seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, and tuberous sclerosis complex (TSC) in patients aged one year and older. Clasepi is the first synthetic CBD of its kind available in India, containing less than 0.1% THC, making it non-psychotropic. Clinical studies have demonstrated its effectiveness in reducing seizures, especially in patients unresponsive to traditional antiseizure medications. The product includes usage guidelines and is not recommended for individuals allergic to cannabidiol or any of its ingredients, with adherence to healthcare provider instructions essential for safe and effective use.

Major companies operating in the epidiolex (cannabidiol) market are Cannoid LLC, Jazz Pharmaceuticals Plc, Curaleaf Holdings Inc., Trulieve Cannabis Corp., Cresco Labs Inc., Tilray Brands Inc., Columbia Care Inc., Canopy Growth Corporation, Acreage Holdings Inc., Verano Holdings Corp., Aurora Cannabis Inc., Planet 13 Holdings Inc., The Cronos Group Inc., Folium Biosciences LLC, Green Roads of Florida LLC, Medterra CBD LLC, Endoca B.V., CV Sciences Inc., NuLeaf Naturals LLC, Isodiol International Inc., PharmaHemp d.o.o., Koi CBD LLC, Elixinol Global Limited, Vapen CBD LLC, 180 Life Sciences Corp.

North America was the largest region in the epidiolex (cannabidiol) market in 2025. The regions covered in the epidiolex (cannabidiol) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the epidiolex (cannabidiol) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the epidiolex (cannabidiol) market by increasing the cost of imported pharmaceutical-grade cannabidiol, excipients, and specialized drug-manufacturing inputs. Hospital pharmacies and retail pharmacies in Asia-Pacific and Latin America are most affected due to heavy dependence on cross-border sourcing of cannabinoid-based ingredients. These higher input costs can raise therapy prices and slow patient access to rare-epilepsy treatments such as lennox-gastaut syndrome and dravet syndrome. However, tariffs are encouraging domestic cannabidiol extraction, formulation, and packaging, strengthening long-term supply security and regulatory compliance.

The epidiolex (cannabidiol) market research report is one of a series of new reports that provides epidiolex (cannabidiol) market statistics, including epidiolex (cannabidiol) industry global market size, regional shares, competitors with a epidiolex (cannabidiol) market share, detailed epidiolex (cannabidiol) market segments, market trends and opportunities, and any further data you may need to thrive in the epidiolex (cannabidiol) industry. This epidiolex (cannabidiol) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Epidiolex is a prescription medication containing cannabidiol (CBD), a compound derived from the cannabis plant. It is primarily used to treat two rare and severe forms of epilepsy, Lennox-Gastaut syndrome (LGS) and Dravet syndrome, in patients aged 1 year and older. Epidiolex helps reduce the frequency and severity of seizures by acting on the endocannabinoid system, although its precise mechanism of action is not fully understood.

The main forms of Epidiolex (cannabidiol) include oral solutions, capsules, and oil solutions. An oral solution is a liquid form of the medication taken by mouth, often used for pediatric patients or individuals who have difficulty swallowing pills. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is applied in the treatment of epilepsy, Dravet syndrome, Lennox-Gastaut syndrome, and overall seizure management.

The epidiolex (cannabidiol) market consists of sales of roasted cannabidiol gummies, vapes, tinctures and sleep aids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.